Compounds > bromopyruvate
Page last updated: 2024-08-25

bromopyruvate and Melanoma

bromopyruvate has been researched along with Melanoma in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Baltazar, F; Bonatelli, M; de Salis, LVV; Dias, MP; Maria-Engler, SS; Pinheiro, C; Pinto, MT; Vital, PDS1
Casal, M; Ko, YH; Niedźwiecka, K; Pedersen, PL; Ułaszewski, S1
Abd-Allah, AA; Ahmed, AS; Ahmed, NS; Amer, WH; El Sayed, SM; Hamed, AR; Helmy Nabo, MM; Mahmoud, AG; Mohamed, WG; Seddik, MA1
Chavez, V; Orue, A; Rieber, M; Strasberg-Rieber, M1
Almaramhy, HH; Ayat, M; Baghdadi, H; Donki, JG; El Sayed, SM; Zolaly, M1
Nickoloff, BJ; Qin, JZ; Xin, H1

Reviews

1 review(s) available for bromopyruvate and Melanoma

ArticleYear
Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study.
    Chinese journal of cancer, 2014, Volume: 33, Issue:7

    Topics: Acetaminophen; Adult; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Glutathione; Glycolysis; Hexokinase; Humans; L-Lactate Dehydrogenase; Lactic Acid; Lung Neoplasms; Male; Melanoma; Necrosis; Neovascularization, Pathologic; Pleural Neoplasms; Prognosis; Pyruvates; Treatment Outcome

2014

Other Studies

5 other study(ies) available for bromopyruvate and Melanoma

ArticleYear
3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells.
    International journal of molecular sciences, 2022, Dec-09, Volume: 23, Issue:24

    Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Melanoma; Mutation; Neoplasm Recurrence, Local; Phenotype; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Vemurafenib

2022
3-Bromopyruvate as a potent anticancer therapy in honor and memory of the late Professor André Goffeau.
    Yeast (Chichester, England), 2019, Volume: 36, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Disease Models, Animal; Fungi; Glycolysis; Hexokinase; Humans; Melanoma; Mitochondria; Multiple Myeloma; Neoplasms; Pyruvates; Pyruvic Acid

2019
Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.
    BMC cancer, 2016, 11-18, Volume: 16, Issue:1

    Topics: A549 Cells; Acetylcysteine; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Free Radical Scavengers; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; GTP Phosphohydrolases; Humans; Lung Neoplasms; Melanoma; Membrane Proteins; Mutation; Proto-Oncogene Proteins p21(ras); Pyruvates; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53

2016
The promising anticancer drug 3-bromopyruvate is metabolized through glutathione conjugation which affects chemoresistance and clinical practice: An evidence-based view.
    Medical hypotheses, 2017, Volume: 100

    Topics: Acetaminophen; Administration, Oral; Albumins; Alkylating Agents; Animals; Antineoplastic Agents; Cisplatin; Drug Resistance, Neoplasm; Evidence-Based Medicine; Glutathione; Humans; Infusions, Intravenous; Melanoma; Models, Theoretical; Pyruvates; Serine

2017
3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell lines.
    Biochemical and biophysical research communications, 2010, May-28, Volume: 396, Issue:2

    Topics: Acetylcysteine; Adenosine Triphosphate; Apoptosis; Cell Line, Tumor; Glutathione; Humans; Melanoma; Membrane Potential, Mitochondrial; Necrosis; Pyruvates; Skin Neoplasms; Superoxides

2010